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A 43-year-old functionally monocular African Amer-
ican woman with longstanding type 2 diabetes
mellitus presented for care of her better-seeing
left eye. Originally suspected of having prolif-
erative diabetic retinopathy (PDR) as the cause
of her bilateral visual impairment, fluorescein
angiography and optical coherence tomography
angiography revealed a marked peripheral non-
perfusion which was out of proportion for a typical
diabetic retinopathy (Figure 1). A comprehensive
uveitic and vasculopathic workup was therefore
initiated. The workup was largely negative except
for hemoglobin electrophoresis, which was consis-
tent with the sickle cell trait (or hemoglobinopa-
thy) (Table 1). The patient was counseled on her
diagnosis and continues to be treated with laser
photocoagulation for her peripheral neovascular-
ization.
Figure 1. Color fundus photo, left eye (A) early (B) and late
(C) fluorescein angiography of the left eye showing marked
peripheral ischemia and posterior pole neovascularization.
OCT angiography (D) showing severely decreased vascular
density.
DISCUSSION
This report strengthens the hypothesis that dia-
betic retinopathy and coexisting vasculopathic
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Table 1. Laboratory assessment of other etiologies for extensive peripheral non-perfusion including pro-thrombotic and
vasculitic causes
Test ordered Result (normal range)
Angiotensin converting enzyme (U/L) 26U/L (8–53 U/L)
Anti-nuclear antibody Negative
Cryoglobulin Negative
Erythrocyte sedimentation rate (mm/H) 60 mm/H high (0–20 mm/H)
HIV Ag and Ab Nonreactive
Anti-myeloperoxidase Negative
Anti PR3 Negative
Rheumatoid factor < 10
Serologic syphilis panel Negative
Anti-thrombin activity 123% (normal)
C-reactive protein (mg/L) 24.9 mg/L high (0–10 mg/L)
Activated protein S (%) 113% (65–150%)
Activated protein C (%) 121% (55–150%)
Factor V Leiden Negative
Homocysteine Negative
Prothrombin time (s) 14.1 s (10.7–15.6 s)
INR (s) 1.1 s (0.8–1.3 s)
CBC Normal
CMP Glucose 353 mg/dL (62–125 mg/dL)
Herpes type 1&2 serology Positive for HSV-1 and HSV-2
CMV (serum antibody) Positive
Hemoglobin electrophoresis Consistent with HbS trait
Quantiferon-TB Gold Negative
CBC, complete blood count; CMP, comprehensive metabolic panel; CMV, antibodies to cytomegalovirus; HIV, human
immunodeficiency virus; INR, international normalized ratio; mg/dL, milligrams per deciliter; mm/H, millimeter per hour U/L, Units
Per Liter
diseases, even sickle cell trait, may have a syner-
gistic effect on the overall disease burden. A broad
differential must be maintained in patients with
presumed diabetic retinopathy, especially those
with uncharacteristic imaging findings.[1–5]
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